RUA Life Sciences Plc (LSE:RUA), the Ayrshire-based maker of implantable medical fabrics and licensor of the Elast-Eon polyurethane, has spent two years reinventing itself from a cash-hungry research company into a contract manufacturer that pays its own way. Interim results published on 30 June 2026 showed the loss before tax for the six months to 31 March 2026 shrinking to £183,000 from £641,000, and adjusted EBITDA turning positive.

The question for AIM investors is whether the group can convert that stability into sustained profit while extracting value from the structural heart Business it spun out in May 2026 and a French urogynaecology unit bought for a nominal sum. At roughly £16m of market value, RUA is small but has several moving parts.

Interim results: loss narrows as the group approaches breakeven

Revenue for the six months ended 31 March 2026 was £2.75m, up 6.1% from £2.59m, with gross Margin improving to 74.9% from 73.5%. Administrative expenses fell 6.2% to £2.31m, the operating loss narrowed to £234,000 from £685,000, adjusted EBITDA swung to a £76,000 profit from a £227,000 loss, and loss per share fell to 0.33p from 1.02p.

Medical Devices and Components Revenue was flat at £2.25m, masking a divergence: the UK contract development and Manufacturing (CDMO) operation grew about 32% to £1.3m, while Abiss, the French subsidiary, fell 23% to £1.0m as its largest customer ran down inventory. Biomaterials revenue rose to £490,000 from £349,000, helped by historical Royalty underpayments uncovered in a licensee audit.

Cash was £2.37m at 31 March 2026, down from £3.25m at the September 2025 year-end after around £0.9m of Working Capital absorption; directors concluded resources are sufficient for at least twelve months. Chairman Geoff Berg said management "has successfully transformed the business from a heavily loss-making, R&D-stage product company into a customer-focused, profitable Contract Manufacturer", and the board anticipates group profitability in the second half.

Just as significant was the 12 May 2026 spin-out of RUA Structural Heart (RSH), which is developing a surgical mitral valve for rheumatic heart disease patients in lower-income countries using the group's AurTex polymer composite. Leducq, a cardiovascular research charity, subscribed for £3m of convertible Loan stock carrying a 5% payment-in-kind coupon, alongside £4.8m of intercompany Debt converted into the same instrument. RUA expects to hold above 62% of RSH after conversions, with a £10m valuation floor for the next round; deconsolidation should produce a non-cash gain of about £4.9m and annual cost savings of roughly £750,000.

What RUA Life Sciences does

Headquartered in Irvine, Scotland, the group was formed in 2020 when AorTech International acquired RUA Medical Devices. RUA Medical is a contract developer and manufacturer of implantable textiles and components, mainly for US device companies. RUA Biomaterials licenses Elast-Eon, a long-term implantable polyurethane, and earns royalties. Abiss, acquired on 6 September 2024 for £68,000 in cash from a distressed vendor, manufactures in France and has its own portfolio in stress urinary incontinence and pelvic floor repair. RUA Vascular develops polymer-sealed grafts and patches; the heart valve programme sits in RSH.

Financial performance: an 18-month period that hit the strategy targets

RUA moved its year-end from March to September, so the last full results, published on 30 January 2026, covered the 18 months to 30 September 2025. Revenue was £6.7m against £2.2m for the twelve months to 31 March 2024, or 104% growth like-for-like, with gross margin of 78.5%. The operating loss narrowed to £0.3m from £1.9m and the loss before tax to £0.2m from £2.0m, although that includes a non-recurring £0.9m bargain purchase gain on Abiss; excluding it, the underlying loss before tax was £1.1m. EBITDA was £0.4m positive against a £1.6m loss, and loss per share was 0.35p versus 4.29p.

Contract manufacturing generated £5.8m of that revenue, split £3.6m from the UK and £2.2m from Abiss, with biomaterials contributing £914,000; North America accounted for 80% of sales. Research and Development spending over the 18 months was £438,000, down from £873,000 in the prior twelve, and removing senior roles saved an estimated £0.6m a year. Cash closed the period at £3.25m with borrowings of £73,000, and Operating Cash Flow was positive in the final six months. No Dividend is paid.

What could drive the shares next

The most immediate catalyst is delivery of second-half profitability in the year to 30 September 2026. Trading updates will show whether the roughly £500,000 of CDMO development contracts identified at the March 2026 AGM, around 60% of which relate to approved or late-stage products, are converting into manufacturing agreements that management says could be worth more than £5m a year if all progress, an aspiration rather than a contracted figure.

A second lever is Abiss, where management is negotiating two years of revenue visibility with its main customer and weighing an RSH-style investor structure as the unit pivots towards its own urogynaecology devices. Funding of RSH's next round at or above the £10m floor would give investors a reference value within a group capitalised at around £16m. Biomaterials could add growth from a new Elast-Eon contract and the royalty audit.

Risks investors should watch

Customer concentration is the clearest risk: Abiss revenue fell 23% in the first half because one customer reduced inventory, and the UK operation likewise serves a limited number of US device makers. With four-fifths of revenue linked to dollar markets, sterling strength also weighs on reported figures.

Cash fell by about £0.9m in six months to £2.37m, and while the RSH structure should deliver a £0.5m net cash benefit in the second half, further working capital build or delays in contract conversion would narrow the cushion. The RSH deal was a convertible loan financing rather than a cash sale, so the £4.9m gain is an accounting item, and RUA's stake will be diluted as instruments convert. Abiss's own product strategy is at an early stage in a field where surgical mesh for incontinence has faced regulatory scrutiny, and RUA is a thinly traded AIM stock with a wide bid-offer spread.

Outlook

RUA has met the two-year targets set in its 2023 strategy review: contract manufacturing is growing, overheads have been cut and the loss-making valve programme has been ring-fenced with external money. The shares have risen from a 52-week low of 10.5p in October 2025 to 26.5p in early September 2026, according to lse.co.uk data.

The next phase depends on execution. Investors should watch for confirmation of second-half profitability, conversion of development contracts into recurring manufacturing revenue, resolution of the Abiss customer issue and external validation of RSH's value. Each would strengthen the case for a self-funding manufacturer with optionality attached; a miss on any would revive the funding questions that dogged the group before 2024.